- Home
- GOSS vs HURA Comparison
GOSS vs HURA Comparison
Compare GOSS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- HURA
- Stock Information
- Founded
- GOSS 2015
- HURA 2009
- Country
- GOSS United States
- HURA United States
- Employees
- GOSS N/A
- HURA N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- GOSS Health Care
- HURA
- Exchange
- GOSS Nasdaq
- HURA Nasdaq
- Market Cap
- GOSS 237.9M
- HURA 246.9M
- IPO Year
- GOSS 2019
- HURA N/A
- Fundamental
- Price
- GOSS $0.96
- HURA $4.79
- Analyst Decision
- GOSS Strong Buy
- HURA Strong Buy
- Analyst Count
- GOSS 5
- HURA 1
- Target Price
- GOSS $9.20
- HURA $11.00
- AVG Volume (30 Days)
- GOSS 1.0M
- HURA 262.4K
- Earning Date
- GOSS 03-04-2025
- HURA 02-15-2025
- Dividend Yield
- GOSS N/A
- HURA N/A
- EPS Growth
- GOSS N/A
- HURA N/A
- EPS
- GOSS N/A
- HURA N/A
- Revenue
- GOSS $105,322,000.00
- HURA N/A
- Revenue This Year
- GOSS N/A
- HURA N/A
- Revenue Next Year
- GOSS N/A
- HURA N/A
- P/E Ratio
- GOSS N/A
- HURA N/A
- Revenue Growth
- GOSS N/A
- HURA N/A
- 52 Week Low
- GOSS $0.50
- HURA $2.84
- 52 Week High
- GOSS $1.60
- HURA $14.60
- Technical
- Relative Strength Index (RSI)
- GOSS 54.23
- HURA N/A
- Support Level
- GOSS $0.83
- HURA N/A
- Resistance Level
- GOSS $1.18
- HURA N/A
- Average True Range (ATR)
- GOSS 0.10
- HURA 0.00
- MACD
- GOSS -0.01
- HURA 0.00
- Stochastic Oscillator
- GOSS 41.37
- HURA 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.